Oncopeptides: Interview with CEO Sofia Heigis

Research Interview



Redeye interviews Oncopeptides' CEO, Sofia Heigis, about how the rights issue is intended to fund the company until breaking even and aspects of the commercial launch of Pepaxti in Europe.


Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.